HeartMate 3: Analysis of Outcomes and Future Directions

IF 2.1 4区医学 Q2 ANESTHESIOLOGY Journal of cardiothoracic and vascular anesthesia Pub Date : 2024-12-01 Epub Date: 2024-08-15 DOI:10.1053/j.jvca.2024.08.016

Juan G. Ripoll MD , Rayssa Becerra Orjuela MD , Jamel Ortoleva MD, FASE , Christoph S. Nabzdyk MD , Serena Dasani MD , Subasish Bhowmik MD , Aditi Balakrishna MD , Stephan Hain MD , Marvin G. Chang MD, PhD , Edward A. Bittner MD, PhD, FCCM , Harish Ramakrishna MD, FACC, FESC

{"title":"HeartMate 3: Analysis of Outcomes and Future Directions","authors":"Juan G. Ripoll MD , Rayssa Becerra Orjuela MD , Jamel Ortoleva MD, FASE , Christoph S. Nabzdyk MD , Serena Dasani MD , Subasish Bhowmik MD , Aditi Balakrishna MD , Stephan Hain MD , Marvin G. Chang MD, PhD , Edward A. Bittner MD, PhD, FCCM , Harish Ramakrishna MD, FACC, FESC","doi":"10.1053/j.jvca.2024.08.016","DOIUrl":null,"url":null,"abstract":"<div><div>Heart failure (HF) remains a public health concern affecting millions of individuals worldwide. Despite recent advances in device-related therapies, the prognosis for patients with chronic HF remains poor with significant long-term risk of morbidity and mortality. Left ventricular assist devices (LVADs) have transformed the landscape of advanced HF management, offering circulatory support as destination therapy or as a bridge for heart transplantation. Among the latest generation of LVADs, the HeartMate 3 has gained popularity due to improved clinical outcomes and lower risk of serious adverse events when compared with previous similar devices. The ELEVATE (Evaluating the HeartMate 3 with Full MagLev Technology in a Post-Market Approval Setting) Registry and the MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) trial represent landmark investigations into the performance and comparative effectiveness of the HeartMate 3 LVAD. This review provides a comprehensive synthesis of the safety and efficacy of the 2-year and 5-year HeartMate LVAD outcomes, highlighting key findings, methodological considerations, implications for clinical practice, and future directions.</div></div>","PeriodicalId":15176,"journal":{"name":"Journal of cardiothoracic and vascular anesthesia","volume":"38 12","pages":"Pages 3224-3233"},"PeriodicalIF":2.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cardiothoracic and vascular anesthesia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053077024005317","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Heart failure (HF) remains a public health concern affecting millions of individuals worldwide. Despite recent advances in device-related therapies, the prognosis for patients with chronic HF remains poor with significant long-term risk of morbidity and mortality. Left ventricular assist devices (LVADs) have transformed the landscape of advanced HF management, offering circulatory support as destination therapy or as a bridge for heart transplantation. Among the latest generation of LVADs, the HeartMate 3 has gained popularity due to improved clinical outcomes and lower risk of serious adverse events when compared with previous similar devices. The ELEVATE (Evaluating the HeartMate 3 with Full MagLev Technology in a Post-Market Approval Setting) Registry and the MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) trial represent landmark investigations into the performance and comparative effectiveness of the HeartMate 3 LVAD. This review provides a comprehensive synthesis of the safety and efficacy of the 2-year and 5-year HeartMate LVAD outcomes, highlighting key findings, methodological considerations, implications for clinical practice, and future directions.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HeartMate 3：成果分析与未来方向。

心力衰竭（HF）仍然是影响全球数百万人的公共卫生问题。尽管最近在设备相关疗法方面取得了进展，但慢性心力衰竭患者的预后仍然很差，长期发病和死亡的风险很大。左心室辅助装置（LVAD）改变了晚期心房颤动治疗的格局，它提供循环支持，既可作为终点治疗，也可作为心脏移植的桥梁。在最新一代的 LVAD 中，HeartMate 3 因与以前的同类设备相比临床效果更好、严重不良事件风险更低而广受欢迎。ELEVATE（在上市审批后环境中评估采用全 MagLev 技术的 HeartMate 3）注册登记和 MOMENTUM 3（MagLev 技术在使用 HeartMate 3 进行机械循环支持治疗的患者中的多中心研究）试验是对 HeartMate 3 LVAD 的性能和比较效果进行的具有里程碑意义的研究。本综述全面综述了 HeartMate LVAD 2 年和 5 年疗效的安全性和有效性，重点介绍了主要发现、方法学考虑因素、对临床实践的影响以及未来发展方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of cardiothoracic and vascular anesthesia 医学-呼吸系统

CiteScore

4.80

自引率

17.90%

发文量

606

审稿时长

37 days

期刊介绍： The Journal of Cardiothoracic and Vascular Anesthesia is primarily aimed at anesthesiologists who deal with patients undergoing cardiac, thoracic or vascular surgical procedures. JCVA features a multidisciplinary approach, with contributions from cardiac, vascular and thoracic surgeons, cardiologists, and other related specialists. Emphasis is placed on rapid publication of clinically relevant material.